Vogenx, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
Vogenx, Inc. (VOGX) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$407.99 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-09-17.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-09-17
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month -$407.99K.
- 2025-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month -$572.65K.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month |
|---|---|
| 2026-06-30 | -$407.99K 10-Q · filed 2026-09-17 |
| 2025-06-30 | -$572.65K 10-Q · filed 2026-09-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |